Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium
ECONOMY & POLICY

Rosatom Scientists Patent Tech for Separating Radium, Actinium, Thorium

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation.

Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as "the future of cancer treatment". Rosatom and healthcare facilities are actively working in this field.

"Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science," said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC.

The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Your next big infra connection is waiting at RAHSTA 2025 – Asia’s Biggest Roads & Highways Expo, Jio World Convention Centre, Mumbai. Don’t miss out!

The technology developed by nuclear scientists has enabled the production of actinium-225 that has a wide application in atomedics. Specialists from the Department of Radionuclide Sources and Preparations at the Research Institute of Nuclear Reactors, State Scientific Centre (RIAR JSC belongs to Rosatom’s Scientific division) have obtained a patent for the technology of producing an actinium-225-based radioactive preparation. Due to its unique properties, the isotope is deemed promising for use in the nuclear medicine and cancer therapy. The production technology ensures the product's high quality, as evidenced during all mandatory stages of monitoring of its specifications. Nowadays, alpha emitters, such as atinium-225, are regarded as one of the most promising areas in the atomedics. These isotopes are often referred to as the future of cancer treatment. Rosatom and healthcare facilities are actively working in this field. Obtaining a patent is a significant milestone for the institute, one of the four global producers of actinium-225. This new development allowed the company, which ranks among the top three at Rosatom, to strengthen its position as an innovation leader. It is also significantly contributing to the advancements in the domestic science, said Andrey Shikunov, Deputy Director for Development and International Business at RIAR JSC. The technology was developed by Dimitrovgrad scientists under an agreement with the Ministry of Industry and Trade of the Russian Federation. The Ministry granted the company a subsidy for scientific research and development following the competitive selection process.

Next Story
Real Estate

Vitizen Hotels Signs Deal at Manyata Tech Park

Vikram Kamats Hospitality, as part of its ongoing expansion in key metropolitan markets, announced that its material subsidiary, Vitizen Hotels, has signed a long-term lease agreement for a 45-key hotel property at Manyata Tech Park, Bengaluru.Strategically located in the city’s prominent IT hub, the property is well-positioned to serve corporate travelers, business professionals, and long-stay guests. The addition aligns with the company’s asset-light growth model, leveraging long-term leases to expand its footprint in high-demand urban markets.The hotel is expected to strengthen the comp..

Next Story
Infrastructure Transport

CONCOR Signs MoU with BPIPL to Operate Container Terminal at Bhavnagar Port

Container Corporation of India (CONCOR) has signed a Memorandum of Understanding (MoU) with Bhavnagar Port Infrastructure (BPIPL) on September 4, 2025, in New Delhi to operate and maintain the upcoming container terminal at the northside of Bhavnagar Port, Gujarat.BPIPL had earlier entered into an agreement with the Gujarat Maritime Board (GMB) in September 2024 for the port’s development. Under this arrangement, 235 hectares of land has been leased to BPIPL for 30 years, with provision for expansion by an additional 250 hectares.The new terminal is expected to significantly enhance logistic..

Next Story
Infrastructure Transport

Concord Launches India’s First Indigenous Zero-Emission Rail Propulsion

Concord Control Systems (CCSL), a leader in embedded electronics and critical rail technologies, has announced the development of India’s first fully indigenous zero-emission propulsion system, marking a significant step toward the country’s railway electrification and net-zero goals for 2030.Powered by Lithium Iron Phosphate (LFP) batteries and featuring a DC chopper-based drive, the propulsion system eliminates idling losses common in diesel engines, offering higher efficiency, lower costs, and zero emissions.What sets this innovation apart is its completely indigenous design. Except for..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?